Expression of MDR1 by Normal Bone Marrow Cells and its Implication for Leukemic Hematopoiesis

References

• Roninson I.B. Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells. Plenum Press, New York, NY 1991
   Google Scholar
• Moscow J.A., Cowan K.H. Multidrug resistance. J. Natl. Cancer Inst. 1988; 80: 14–20
   PubMed Web of Science ®Google Scholar
• Pastan I., Gottesmann M. Multiple-drug resistance in human cancer. N. Engl. J. Med. 1987; 316: 1388–1393
   PubMed Web of Science ®Google Scholar
• Marie J.P., Zittoun R., Sikic B.I. Multidrug-resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 1991; 78: 586–592
   PubMed Web of Science ®Google Scholar
• Pirker R., Wallner J., Geissler K., Linkesch W., Haas O.A., Bettelheim P., Hopfner M., Scherrer R., Valent P., Havelec L., Ludwig H., Lechner K. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J. Natl. Cancer Inst. 1991; 83: 708–712
   PubMed Web of Science ®Google Scholar
• Campos L., Guyotat D., Archimbaud E., Calmard-Oriol P., Tsuruo T., Trancy J., Treille D., Fiere D. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992; 79: 473–476
   PubMed Web of Science ®Google Scholar
• Zhou D.-C, Marie J.-P., Suberville A.-M., Zittoun R. Relevance of mdr1 gene expression in acute myeloid leukemia and comparison of different diagnostic methods. Leukemia 1992; 6: 879–885
   PubMed Web of Science ®Google Scholar
• Pileri S.A., Sabattini E., Falini B., Tazzari P.L., Gherlinzoni F., Michieli M., Damiani D., Zucchini L., Gobbi M., Tsuruo T., Baccarani M. Immunohistochemical detection of the multidrug transport protein PI70 in human normal tissues and malignant lymphomas. Histopathology 1991; 19: 131–140
   PubMed Web of Science ®Google Scholar
• Cheng A.-L., Su I.-J., Chen Y.-C., et al. Expression of P-glycoprotein and glutathione-S-transferase in recurrent lymphomas: The possible role of Epstein-Barr virus, immunophenotypes, and other predisposing factors. J. Clin. Oncol. 1993; 11: 109–115
   PubMed Web of Science ®Google Scholar
• Epstein J., Xiao H., Oba B. P-glycoprotein expression in plasma cell myeloma is associated with resistance to VAD. Blood 1989; 74: 913–916
   PubMed Web of Science ®Google Scholar
• Dalton W.S., Grogan T.M., Meltzer P.S., Scheper R.J., Durie B.G., Taylor C.W., Miller T.P., Salmon S.E. Drug resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J. Clin. Oncol. 1989; 7: 415–424
   PubMed Web of Science ®Google Scholar
• Miller T.P., Grogan T.M., Dalton W.S., et al. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J. Clin. Oncol. 1991; 9: 17–24
   PubMed Web of Science ®Google Scholar
• Salmon S.E., Dalton W.S., Grogan T.M., et al. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood 1991; 78: 44–50
   PubMed Web of Science ®Google Scholar
• Yahanda A.M., Adler K.M., Fisher GA., Brophy N.A., Halsey J., Hardy R.I., Gosland M.P., Lum B.L., Sikic B.I. Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J. Clin. Oncol. 1992; 10: 1624–1633
   PubMed Web of Science ®Google Scholar
• Sonneveld P., Durie B.G.M., Lokhorst H.M., Marie J.-P., Solbu G., Suciu S., Zittoun R., Loöwenberg B., Nooter K. Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 1992; 340: 255–259
   PubMed Web of Science ®Google Scholar
• Marie J.P., Bastie J.N., Coloma F., Suberville A.M.F., Delmer A., Rio B., Delmas-Marsalet B., Leroux G., Casassus P., Baumelou E., Catalin J., Zittoun R. Cyclosporin A as a modifier agent in the salvage treatment of acute leukemia. Leukemia 1993; 7: 821–824
   PubMed Web of Science ®Google Scholar
• List A.F., Spier C., Greer J., Wolff S., Hutter J., Dorr J., Salmon S., Futscher B., Baier M., Dalton W. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J. Clin. Oncol. 1993; 11: 1652–1660
   PubMed Web of Science ®Google Scholar
• Chaudary P.M., Roninson I.B. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991; 66: 85–94
   PubMed Web of Science ®Google Scholar
• Drach D., Zhao S., Drach J., Mahadevia R., Gattringer C., Huber H., Andreeff M. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 1992; 80: 2729–2734
   PubMed Web of Science ®Google Scholar
• Chaudary P.M., Mechetner E.B., Roninson I.B. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992; 80: 2735–2739
   PubMed Web of Science ®Google Scholar
• Marie J.P., Brophy N.A., Ehsan M.N., Aihara Y., Mohamed N.A., Cornbleet J., Chao N.J., Sikic B.I. Expression of multidrug resistance gene mdr 1 mRNA in a subset of normal bone marrow cells. Br. J. Haematol. 1992; 81: 145–152
   PubMed Web of Science ®Google Scholar
• Ludescher C., Thaler J., Drach D., Drach J., Spitaler M., Gattringer C., Huber H., Hofmann J. Detection of activity of P-glycoprotein in human tumour samples using rhodamine 123. Br. J. Haematol 1992; 82: 161–168
   PubMed Web of Science ®Google Scholar
• Körbling M., Drach J., Champlin R.E., Engel H., Huyen L., Kleine H.D., Berenson R., Deisseroth A.B., Andreeff M. Large-scale preparation of highly purified, frozen/thawed CD34+, HLA-DR- hematopoietic progenitor cells by sequential immunoadsorption (CEPRATE SC) and fluorescence-activated cell sorting: implications for gene transduction and/or transplantation. Bone Marrow Transplantion 1994, in press
   PubMedGoogle Scholar
• Chin K.-V., Ueda K., Pastan I., Gottesmann M.M. Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Science 1991; 255: 459–462
   Web of Science ®Google Scholar
• Zhao S., Drach D., Hu G., Squires J., Drach J., Deisseroth A., Andreeff M. Absence of regulation of mdr1 by p53 in normal hematopoiesis and acute myelogenous leukemia. Blood 1992; 80: 202a, Suppl. 1
   Google Scholar
• Andreeff M., Zhao S., Drach D., Hegewisch-Becker S., Rees J.H.K., Liu Y., Hanania E.G., Körbling M., Deisseroth A.B., Drach J. Expression of multidrug resistance (mdr-1) and p53 genes in hematologic cell systems: Implications for biology and gene therapy. Cancer Bulletin 1993; 45: 131–138
   Google Scholar
• Chaudhary P.M., Roninson I.B. Activation of MDR1 (P-glycoprotein) gene expression in human cells by protein kinase C agonists. Oncology Res. 1992; 4: 281–290
   PubMed Web of Science ®Google Scholar
• Farrar W.L., Thomas T.P., Anderson W.B. Altered cytosol/membrane enzyme redistribution on interleukin-3 activation of protein kinase C. Nature 1985; 315: 235–237
   PubMed Web of Science ®Google Scholar
• Morla A.O., Schreurs J., Miyajima A., Wang J.Y.J. Hematopoietic growth factors activate the tyrosine phosphorylation of distinct sets of proteins in interleukin-3-dependent murine cell lines. Mol. Cell. Biol. 1988; 8: 2214–2219
   PubMed Web of Science ®Google Scholar
• Andreeff M., Drach J., Zhao S., Consoli U., Escudier S., Sanchez-Williams G., Liu Y., Goodacre A., Drach D., Dunne C., Tafuri A., Estey E., Deisseroth A. Cell kinetic, molecular and clinical analysis of growth factor sensitization of myeloid leukemia. Hemopoietic growth factors, oncogenes and cytokines in clinical hematology, E. Cacciola, A.B. Deisseroth, R. Giustolisi. Karger, Basel 1994; 112–136
   Google Scholar
• Drach D., Zhao S., Drach J., Andreeff M. Low incidence of MDR1 expression in acute promyelocytic leukemia. 1994, Submitted for publication
   Google Scholar
• te Boekhorst P.A.W., de Leeuw K., Schoester M., Wittebol S., Nooter K., Hagemeijer A., Lowenberg B., Sonneveld P. Predominance of functional multidrug resistance (MDR1) phenotype in CD34+ acute myeloid leukemia cells. Blood 1993; 82: 3157–3162
   PubMed Web of Science ®Google Scholar